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effect of same-day discharge after elective endovascular aneurysm repair
(EVAR) for abdominal aortic aneurysm (AAA).
Methods: All elective EVAR from January 2012 to June 2013
were identiﬁed. Demographics, comorbidities, complications, nursing
care, ﬁnancial data, and length of stay (LOS) were analyzed (SPSS
21).
Results: The Table presents the care received in 67 elective EVAR
(70% percutaneous EVAR; 61% of AAA). Intraoperative and postopera-
tive complications were type I endoleak, 1.5%; thrombosis, 3%; blood
loss requiring transfusion, 4.5%; urinary retention, 4.5%; myocardial
infarction, 3%; and hemodynamic/rhythm alterations, 37% (evident in
88% [n ¼ 24] <6 hours; 13% required therapy). Monitoring only was
needed in 28 patients (42%) and intensive care unit in 13.4%. Postoper-
ative day 1 discharge occurred in 73%; 7.5% <30-day readmission. Total
hospital costs were $29,479: operating room, 80.3%; anesthesia, 2.2%;
preadmission, 1%; postanesthesia unit, 3.1%; intensive care unit, 1.9%;
ﬂoor, 4.7%; laboratory/diagnostic tests, 1.2%; pharmacy, 1.4%; other,
4.2%. Total cost was similar for those discharged <24 or >25 hours post-
operatively (P ¼ .09) and for monitoring only vs others ($28,146 vs
$30,545; P ¼ .12). Pharmacy ($351 vs $509: P ¼ .05) and laboratory
($86 vs $354: P ¼ .01) and diagnostic testing ($4 vs $254: P ¼ .02)
were lower for uncomplicated cases.
Conclusions: Same-day discharge is clinically feasible in >40% of
elective EVAR but requires coordination for adequate postoperative moni-
toring. Signiﬁcant savings are unlikely because most of the cost is operating
room/device-related, and further reduction of costs in uncomplicated cases
is unlikely.Table. Postoperative services used by the sample
Indicator % Mean hours post-op
Oxygen 98.5 19
Telemetry 100 12
Arterial catheter 27.3 10
Intravenous
Continuous 86.4 12.5
Fluid bolus 16.7 4.5 (initiated)
Medication 52.4
Indwelling urinary catheter 67.2 19
Straight catheterization 4.5 14 (initiated)
<3 laboratory assessments 76.2
Diabetic management 31.3
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Objectives: Transcatheter aortic valve replacement (TAVR) is a Food
and Drug Administration-approved means of treating symptomatic aortic
stenosis in high-risk patients. A number of techniques to deliver valve pros-
theses are currently in practice, including transfemoral (TF), transapical, and
transaortic approaches. Various disciplines are involved throughout this
complex process. Our team includes a vascular surgeon, bringing greater
experience in aortoiliac imaging, vascular access, and repair. We analyzed
the role of a vascular surgeon during the selection process and throughout
safe device delivery.
Methods: Patients who underwent TAVR between May 2012 and
January 2014 were identiﬁed from a prospective database. Vascular complica-
tions included hematoma, vessel injury, wound infection, pseudoaneurysm,
vessel thrombosis, and retained delivery sheath. Differences in the quantitative
analysis and radiographic interpretation of access vessels between the radiolo-
gist and the vascular surgeon were evaluated. These differences were analyzed
to determine if (1) it led to more cases being performed via a TF route and if
(2) it resulted in a greater number of vascular complications.>Eastern Vascular SocietyResults: A total of 156 TAVRs were completed during the study
period. Ninety-nine cases (63%) were performed TF. Nine major vascular
complications (6%) were observed #30 days of surgery. Of the eight
vascular complications within the TF group, six (75%) involved the surgical
side, and two (25%) occurred on the diagnostic side. Complications occur-
ring in the surgical exposure side included 1 hematoma, 1 wound infection,
2 patients with external iliac lacerations, and 1 patient requiring external iliac
to common femoral interposition graft because the sheath was unable to be
removed and the artery was severely damaged. The last complication
involved conversion to a TA approach because the delivery sheath would
not advance through the iliac artery.
Conclusions: Studies have cited the incidence of major vascular com-
plications during TAVR as high as 23%. At our center, the observed number
of complications occurred in only 6% of TAVRs. Currently, with only larger-
proﬁle devices available to institutions not involved in trials, our results
support a role for the importance of a vascular surgeon as a member of a suc-
cessful TAVR team. With the advent of lower-proﬁle devices, complication
rates may decline, but more patients with compromised access vessels may
be selected for a TF approach, thus further strengthening the role of a
vascular surgeon.
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Objectives: Complex endovascular interventions such as aortic stent
grafts and carotid artery stenting are often performed in patients with chal-
lenging anatomy and severe comorbidities. It is thus of critical importance
to increase anatomic accuracy and limit contrast dose and operative time.yNew England Society for Vascular Surgery
Fig. Primary and secondary patency of bypass vs stent graft repair.
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plex endovascular interventions by creating a three-dimensional (3D) road-
map from a previously obtained computed tomography angiography
(CTA).
Methods: After informed consent, patients were prepared for inter-
vention in the usual fashion. Next a 3D roadmap was established: (1) semi-
automatic segmentation of the vasculature of interest on the existing CTA,
(2) selection of C-arm angles, (3) placement of markers identifying points of
interest such as branch origins, (4) 2D or 3D ﬂuoroscopic registration and
merging with CTA. This 3D roadmap, including programmed angles and
landmarks, was then used to perform the intervention. Fluoroscopy time
(minutes), air kerma (mGy), and contrast amount (mL) were collected.
EVAR data were compared with control patients.
Results: Fluoroscopy times, air kerma and contrast for VesselNavigator
for EVAR vs control were 19.976 10.06 vs 31.026 19.8 minutes (P¼ .02),
1300.47 6 661.66 vs 1543.95 6 1139.27 mGy (P ¼ .24), and 45.72 6
33.46 vs 67.76 6 35.73 mL (P ¼ .03), respectively. VesselNavigator was
also tested in 4 fenestrated endovascular aneurysm repairs, 5 thoracic endo-
vascular aortic repairs, 8 carotid artery stent procedures, and in 21 emboliza-
tions. In all cases, live 3D navigation allowed for expeditious and safe
identiﬁcation and selection of structures of interest, such as branch origins,
facilitating sheath delivery into the carotid or renal arteries. Preprogrammed
projection angles yielded short ﬂuoroscopy times and provided optimal visu-
alization of points of interest. The technology also allowed for maintenance of
the roadmap while moving the table and changing projection angles (Fig).
Conclusions: VesselNavigator, a novel software package to create 3D
roadmaps, is simple to use, reliable, and fast. It displays points of interest
robustly and thus has the potential to substantially reduce the amount of
contrast and ﬂuoroscopy time. It obviates the need for traditional and pro-
longed angiograms.
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Laser Atherectomy: Long-Term Clinical Results for the Treatment of
Peripheral Arterial Disease>
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Objectives: This study investigated the long-term clinical results of
laser atherectomy in the treatment of peripheral arterial disease.
Methods: This was a retrospective analysis of consecutive patients un-
dergoing laser atherectomy at a tertiary university-afﬁliated hospital during a
7-year period by vascular surgeons and interventional cardiologists. Clinical
data were retrieved from patient records and hospital electronic medical re-
cords along with the associated arteriograms.
Results: A total of 461 lesions in 343 limbs were treated in 300 pa-
tients with a mean age of 70 years. The indication was critical limb ischemia
(CLI) with rest pain or tissue loss in 227 (66%) of interventions and claudi-
cation in 116 (34%). All procedures included an associated balloon angio-
plasty, and stenting was performed in 33%.Technical success was achieved
in 99%, with only two patients (<1%) with an acute procedure-related
complication requiring surgical intervention. At a mean follow up of 28
months, 156 patients (45%) became asymptomatic or achieved signiﬁcant
clinical improvement (resolution of tissue loss or rest pain), 60 (17%)
remained with CLI, 30 (9%) had a major proximal amputation, and 18
(5%) had a minor amputation. Freedom from major amputation was 90%
at 5 years by life-table analysis. Univariate statistical analysis demonstrated
the risk of a major amputation was associated with diabetes, hemodialysis,
and tissue loss (P < .05 to P < .005), whereas multivariate logistic regres-
sion analysis indicated diabetes to be overwhelmingly important (RR, 4.84;
95% conﬁdence interval [CI], 1.1-21.3; P < .05). In a similar manner,
multivariate analysis indicated dialysis (RR, 2.46; 95% CI, 1.01-5.98; P <
.05) and CLI (RR, 2.27; 95% CI, 1.42-3.65; P < .01) were associated
with higher likelihood for lack of clinical improvement. There was no differ-
ence in major amputation rates between surgeons and interventional cardi-
ologists (RR, 1.5; 95% CI; P < .1), although patients treated by surgeons
were three times more likely to suffer from CLI (odds ratio, 3.2; 95% CI,
1.9-5.4; P < .0001).
Conclusion: Laser atherectomy is safe and efﬁcacious in limb salvage.
Diabetic patients have much higher probability of requiring a proximal
amputation, whereas those on dialysis and with CLI are least likely to
gain clinical beneﬁt. Surgeons treated patients with more advanced disease.>Eastern Vascular SocietyDisclosures: A. Mallios: Nothing to disclose; J. Blebea: Nothing to
disclose; R. Messiner: Nothing to disclose; K. Taubman: Nothing to
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Objectives: Popliteal aneurysms can be treated by open bypass or
endovascular stent graft placement. Data comparing the two methods are
limited. We compared bypass with stent grafting during a 7-year period.
Methods: A retrospective analysis was performed from 2007 to 2013
of all popliteal aneurysm repairs. Demographics, anatomic characteristics,
and outcomes for patients undergoing open bypass with vein or prosthetic
grafts (medial or posterior approach) or endovascular stent grafting were
analyzed and compared.
Results: There were 31 bypass and 21 stent graft patients. In 2007,
only one stent graft repair was performed (11%), whereas in 2013, six were
performed (75%). The bypass patients were younger than those receiving
stent grafts (67.4 6 11.0 vs 77.5 6 7.1 years, P < .05). All patients were
male with similar comorbidities. Pain symptoms were present in 52% of
bypass patients vs in 29% of stent graft patients (P ¼ .1). Half of all patients
underwent contralateral popliteal aneurysm repair (81% with bilateral
popliteal aneurysms and 54% with concomitant abdominal aortic aneu-
rysm). There was no difference in mean aneurysm diameter between repairyNew England Society for Vascular Surgery
